Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Neuralstem (CUR) Competitors

Neuralstem logo

CUR vs. SRNE, SQZ, GNCAQ, GNCA, ELOX, PRME, PLX, IKT, IZTC, and CVM

Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), and CEL-SCI (CVM). These companies are all part of the "medical" sector.

Neuralstem vs. Its Competitors

Neuralstem (NASDAQ:CUR) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Neuralstem has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260K4.87-$4.93MN/AN/A
Sorrento Therapeutics$60.32M0.05-$572.84MN/AN/A

In the previous week, Neuralstem's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Neuralstem Neutral
Sorrento Therapeutics Neutral

38.3% of Neuralstem shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sorrento Therapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Sorrento Therapeutics' return on equity of 0.00% beat Neuralstem's return on equity.

Company Net Margins Return on Equity Return on Assets
Neuralstem-39,417.64% -170.51% -110.16%
Sorrento Therapeutics N/A N/A N/A

Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Summary

Neuralstem beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Neuralstem News Delivered to You Automatically

Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CUR vs. The Competition

MetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$1.27M$291.42M$5.73B$10.28B
Dividend YieldN/AN/A5.88%4.63%
P/E RatioN/AN/A76.7426.53
Price / Sales4.87422.05526.07121.12
Price / CashN/A22.4437.2060.52
Price / Book0.099.9813.946.31
Net Income-$4.93M-$111.61M$3.29B$271.37M

Neuralstem Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CUR
Neuralstem
N/A$0.60
+1.8%
N/A-84.9%$1.27M$260K0.006Gap Down
SRNE
Sorrento Therapeutics
0.9144 of 5 stars
$0.00
-42.9%
N/A+0.0%$1.10M$60.32M0.00800Gap Up
SQZ
SQZ Biotechnologies
N/A$0.03
flat
N/A-30.0%$826K$18.16M-0.011,620
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$6KN/A0.0070
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91M0.0070News Coverage
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/A$0.00N/A0.0030
PRME
Prime Medicine
3.3286 of 5 stars
$3.89
-5.6%
$8.92
+129.2%
+24.9%$523.49M$4.96M-1.90234News Coverage
Options Volume
Gap Up
PLX
Protalix BioTherapeutics
2.3405 of 5 stars
$1.69
-1.7%
$15.00
+787.6%
+78.9%$134.75M$61.95M-13.00200
IKT
Inhibikase Therapeutics
1.3196 of 5 stars
$1.54
-7.8%
$6.50
+322.1%
+34.5%$114.76MN/A-0.586
IZTC
Invizyne Technologies
N/A$11.76
-2.0%
N/AN/A$73.52MN/A0.0029
CVM
CEL-SCI
1.319 of 5 stars
$9.68
-9.4%
N/A-73.0%$66.62MN/A-20.1743Positive News
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:CUR) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners